Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Meta Expands AI Training With Employee Activity Tracking Tools 
LOS ANGELES, March 31, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq:SCYX) concerning possible violations of federal securities laws. Investors who purchased SCYNEXIS securities: (1) pursuant or traceable to the Company’s initial public offering on or about May 2, 2014; and/or (2) from May 2, 2014 through March 2, 2017, inclusive (the “Class Period”) should contact the firm prior to the May 8, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint states that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company’s lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug’s approval prospects and/or commercial viability; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation. When this information reached the investing public, shares of SCYNEXIS dropped in value, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
